

[2 + 2] Cycloadditions of Electron-Poor Acetylenes to (5*Z*)-5-[(Dimethylamino)methylene]imidazolidine-2,4-diones

by Uroš Uršič, Uroš Grošelj, Anton Meden, Jurij Svete, and Branko Stanovnik*

Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, P.O. Box 537, 1000 Ljubljana, Slovenia
(e-mail: branko.stanovnik@fkkt.uni-lj.si)


Microwave-assisted [2 + 2] cycloadditions of acetylene mono- and acylenedicarboxylates **2** to (5*Z*)-5-[(dimethylamino)methylene]imidazolidine-2,4-dione **4a** or to the corresponding thioxo derivative **4b** in MeCN furnished the highly functionalized imidazolidine-2,4-dione derivatives **5** and **6** or the corresponding thioxo derivatives **5–7** as single isomers or mixtures of two isomers (*Schemes 2* and *3*, *Table 1*). When the reaction of (5*Z*)-5-[(dimethylamino)methylene]imidazolidine-2,4-dione (**4c**) with acylenedicarboxylate **2a** was performed in DMF, hydrolysis of the (dimethylamino)methylene group took place to give (2*E*)-2-(2,5-dioxoimidazolidin-4-ylidene)butanedioate **11** (*Scheme 5*).

Introduction. – In the last few decades, there have been some reports of reactions of simple tertiary enamines with electron-poor acetylenes, such as alkyl propiolates (=alkyl prop-2-ynoates) and dialkyl acylenedicarboxylates (=dialkyl but-2-ynedioates) [1]. It has been generally accepted that these reactions initially proceed by a [2 + 2] cycloaddition. However, the structure of the final product is strongly dependent on the structure of the starting compound and reaction conditions [1d]. The geometry of the obtained products was, in some cases, unambiguously determined by *Reinholdt* and co-workers in the early eighties [1d]. When these reactions were extended to other functionalized enamines and enaminones, in some cases, a *Michael*-type addition took place preferentially over the [2 + 2] cycloaddition [2].

The 3-(dimethylamino)propenoates and related enaminones have been demonstrated to be useful building blocks in the synthesis of many heterocyclic systems [3], including the preparation of natural products and their analogs, such as aplysinopsins [4], meridianines [5], dipodazines [6], and tryprostatins [7]. We have also reported an efficient method for the preparation and functionalization of highly substituted 1-amino-2,3-dihydro-1*H*-pyrrole, 1-amino-1*H*-pyrrole, and fused pyrrolo[3,2-*d*]oxazole systems from '1,2-diazabuta-1,3-dienes' and 3-(dimethylamino)prop-2-enoates [8] and the regio- and stereoselective one-pot synthesis of oxazolo-fused pyridazines *via* a 'Michael-addition – pyridazine-cyclization – oxazoline cyclization' cascade reaction [9].

As an extension of our research, we recently reported on microwave assisted regiospecific [2 + 2] cycloadditions of electron-poor acetylenes **2** to (2*Z*)-2-(acylamino)-3-(dimethylamino)prop-2-enoates **1**, which resulted in the formation of (1*E*,3*E*)-1-(acylamino)-4-(dimethylamino)buta-1,3-dienes **3** (*Scheme 1*) [10].


Scheme 1



Results and Discussion. – Since (5*Z*)-5-[(dimethylamino)methylene]imidazolidine-2,4-diones **4a,c** and the corresponding thioxo derivative **4b** have already been established as very useful intermediates in the synthesis of natural products such as aplysinopsins [4], we report in this article on [2+2] cycloadditions of electron-poor acetylenes **2a–2d** to these compounds, which are cyclic analogues of (2*Z*)-2-(acylamino)-3-(dimethylamino)prop-2-enoates **1** [10].

When (5*Z*)-5-[(dimethylamino)methylene]-3-methylimidazolidine-2,4-dione (**4a**) and acetylenedicarboxylates (= but-2-ynedioates) **2a,b** were heated in MeCN under microwave (MW) irradiation, (2(1')*E*,3(4'')*E*)-2-[(dimethylamino)methylene]-3-(1-methyl-2,5-dioxoimidazolidin-4-ylidene)butanedioates **5a,b** were formed as the only isomers. On the other hand, the reactions of imidazolidine-2,4-dione **4a** with electron-poor but-2-ynoate **2c** and of (5*Z*)-5-[(dimethylamino)methylene]-3-phenyl-2-thioxoimidazolidin-4-one (**4b**) with acetylene derivatives **2a,c** produced mixtures of two isomers. In these cases, the major (2(1')*E*,3(4'')*E*)-isomers **5c–5d** were accompanied by (2(1')*E*,3(4'')*Z*)-isomers **6c–6d** (Scheme 2, Table 1).

Scheme 2

Table 1. Synthesis of Compounds **5a–5e** and **6c–6e**

5, 6	R ¹	X	R ²	R ³	Yield [%]	5/6	Time [min]
a	Me	O	COOMe	COOMe	84	100 : 0	120
b	Me	O	COOEt	COOEt	62	100 : 0	120
c	Ph	S	COOMe	COOMe	89	54 : 46	120
d	Me	O	CF ₃	COOEt	97	65 : 35	120
e	Ph	S	CF ₃	COOEt	95	54 : 46	60

The structures of products **5** and **6** were determined by elemental analysis, IR, ¹H- and ¹³C-NMR, HMBC technique, HR-MS, and X-ray analysis. The configurations of the C(2)=C(1') bond of compounds **5a,d** and **6d** were established by the 2D-HMBC

NMR technique. The magnitude of the heteronuclear coupling constant, $^3J(\text{C,H})$, for nuclei $\text{O}=\text{C}-\text{C}=\text{C}-\text{H}$ with *cis* configuration of the $\text{C}=\text{C}$ bond are smaller (2–6 Hz) than those for the *trans*-oriented ones (8–12 Hz) [3b,d][11]. Accordingly, the heteronuclear coupling constant of compounds **5a,d** and **6d** indicate the (*2E*)-configuration (Fig. 1). The same (*2E*)-configurations of the $\text{C}(2)=\text{C}(1')$ bonds indicate that isomers **5** and **6** differ in the configuration of the $\text{C}(3)=\text{C}(4')$ bonds. Additionally, the structures of both isomers **5d** (Fig. 2) and **6d** (Fig. 3) were confirmed by X-ray analysis.




Fig. 1. Coupling constant $^3J(\text{C,H})$ of the $\text{O}=\text{C}-\text{C}=\text{C}-\text{H}$ moiety of **5a,d** and **6d**




Fig. 2. ORTEP View of compound **5d** at the 50% probability level. H-Atoms are drawn as spheres of arbitrary radii. The molecule of the co-crystallized solvent (CHCl_3) is omitted for clarity. Very large displacement parameters of C(223) indicate disorder of the Me group and a somewhat lower quality of the crystals; the molecular geometry is, however, unambiguous.

The reaction of **4b** with ethyl propiolate (= ethyl prop-2-ynoate; **2d**) also furnished a mixture of two isomers **5f** and **7f** (Scheme 3). However, in this case, the major (*2(4')E,3Z*)-isomer **5f** was accompanied by the minor (*2(4')E,3E*)-isomer **7f**, which is





Fig. 3. ORTEP View of compound **6d** at the 50% probability level. H-Atoms are drawn as spheres of arbitrary radii.

Scheme 3



structurally different from the minor isomers **6c–6e** mentioned previously. The structures of isomers **5f** and **7f** were determined by $^1\text{H-NMR}$ spectroscopy, where characteristic coupling constants for *cis*-oriented ($^3J(\text{H,H}) = 10.1 \text{ Hz}$) and *trans*-oriented protons ($^3J(\text{H,H}) = 15.9 \text{ Hz}$) were observed (Fig. 4).

Two major pathways can be envisioned for the cycloadditions of acetylenes **2** to **4**, a concerted and a stepwise one. In the case of a concerted cycloaddition, the reaction should proceed as a $[2_s + 2_a]$ cycloaddition resulting in cyclobutene intermediate **9'**, which would undergo a conrotatory *retro*-electrocyclization to afford the (2(1')*E*,3(4'')*Z*)-isomer **6** ($\text{R}^3 \neq \text{H}$) and/or (2(1')*Z*,3(4'')*E*)-isomer **7** ($\text{R}^3 \neq \text{H}$), or (2(4')*Z*,3*Z*)-isomer **6** ($\text{R}^3 = \text{H}$) and/or (2(4')*E*,3*E*)-isomer **7** ($\text{R}^3 = \text{H}$). In the two-step mechanism, the initially formed intermediate **8** can cyclize to cyclobutene **9'** or it may be transformed into intermediate **8'**, which cyclizes to cyclobutene intermediate **9**. From the latter, two different products can be formed by conrotatory *retro*-electrocyclization, *i.e.*, (2(1')*E*,3(4'')*E*)-isomer **5** ($\text{R}^3 \neq \text{H}$) and/or (2(1')*Z*,3(4'')*Z*)-isomer **10**





Fig. 4. Coupling constant $^3J(\text{H,H})$ of the H–C=C–H moiety of **5f** and **7f**

($\text{R}^3 \neq \text{H}$), or (2(4')*E*,3*Z*)-isomer **5** ($\text{R}^3 = \text{H}$) and/or (2(4')*Z*,3*E*)-isomer **10** ($\text{R}^3 = \text{H}$) (Scheme 4). The obtained results indicate that these cycloadditions proceed by a

Scheme 4



stepwise mechanism. In the cases, where the single products **5a,b** were formed, the intermediate **8** is completely transformed into intermediate **8'**, while in the cases where mixtures of two isomers were obtained, this transformation from **8** to **8'** is not complete, and some cyclobutene intermediate **9'** is formed as well.

Contrary to **4a,b**, (5*Z*)-5-[(dimethylamino)methylene]imidazolidine-2,4-dione (**4c**) did not react with dimethyl acetylenedicarboxylate (**2a**) in MeCN, probably due to its insolubility. When **4c** was treated with **2a** in DMF at 80°, dimethyl (2*E*)-2-(2,5-dioximidazolidin-4-ylidene)butanedioate (**11**) was obtained (Scheme 5). This can easily be explained by the initial formation of dimethyl (2*E*,3*E*)-2-[(dimethylamino)methylene]-3-(2,5-dioximidazolidin-4-ylidene)butanedioate (**5g**) which, under the experimental conditions, was hydrolyzed to **11** and DMF. The structure of **11** was confirmed by X-ray-analysis (Fig. 5). The configuration of the C(2)=C(4') bond in compound **11** confirms the proposed structure and consequently the mechanism of these cycloadditions.





Fig. 5. ORTEP View of compound **11** at the 50% probability level. H-Atoms are drawn as spheres of arbitrary radii.

Conclusions. – The [2 + 2] cycloaddition of electron-poor acetylenes **2** with (5*Z*)-5-[(dimethylamino)methylene]imidazolidine-2,4-diones **4a,c** or the corresponding thio-

xo derivative **4b** was established as an easy and efficient synthetic route to highly functionalized imidazolidine-2,4-diones, which offer wide possibilities for further transformations.

The financial support from the *Slovenian Research Agency* through grants P1-0179 and J1-0972 is gratefully acknowledged. We thank the pharmaceutical companies *Krka d.d.*, Novo mesto, Slovenia, and *Lek d.d.*, a *Sandoz* company, Ljubljana, Slovenia for the financial support. Crystallographic data were collected on a *Kappa-CCD-Nonius* diffractometer in the Laboratory of Inorganic Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Slovenia. We acknowledge with thanks the financial contribution of the *Ministry of Science and Technology*, Republic of Slovenia through grant Packet X-2000 and PS-511-102, which made the purchase of the apparatus possible.

Experimental Part

General. The acetylene derivatives **2a–2d** are commercially available (*Sigma-Aldrich*). (5*Z*)-5-[(Dimethylamino)methylene]-3-methylimidazolidine-2,4-dione (**4a**) [4a], (5*Z*)-5-[(dimethylamino)methylene]-3-phenyl-2-thioxoimidazolidin-4-one (**4b**) [12], and (5*Z*)-5-[(dimethylamino)methylene]-imidazolidine-2,4-dione (**4c**) [4a] were prepared according to literature procedures. Microwave irradiations were performed in a *CEM-Corporation-Discover* microwave unit. Column chromatography (CC): silica gel 60 (0.04–0.06 mm; *Fluka*). Medium-pressure liquid chromatography (MPLC): silica gel 40 (0.015–0.035 mm; *Merck*), column size 15 × 460 mm; *Büchi* isocratic system with UV detection (UV detector *K-2001*; *Knauer*) at 254 nm. Melting points: *Kofler* micro hot stage. IR Spectra: *Perkin-Elmer-Spectrum-BX-FTIR* spectrophotometer; $\tilde{\nu}$ in cm^{-1} . NMR Spectra: *Bruker-Avance-DPX-300* spectrometer; at 300 MHz for ^1H and 75.5 MHz for ^{13}C , (D_6)DMSO and CDCl_3 as solvents and Me_4Si as the internal standard; δ in ppm, J in Hz. MS: *AutoSpecQ* and *Qtof-premier* spectrometers; in *m/z*. Microanalyses: *Perkin-Elmer-CHN* analyser 2400 II.

Imidazolidine Derivatives 5a–5f, 6c–6e, and 7f: General Procedure. Acetylene **2a–2d** was added to a soln. of (5*Z*)-5-[(dimethylamino)methylene]imidazolidine derivative **4a,b** in MeCN (4 ml), and the mixture was stirred in a closed vessel under microwave irradiation at constant temp. The mixture was cooled, volatile components were evaporated, and the residue was purified by CC (silica gel).

Dimethyl (2E,3E)-2-[(Dimethylamino)methylene]-3-(1-methyl-2,5-dioxoimidazolidin-4-ylidene)butanedioate (5a). Prepared from **4a** (0.169 g, 1 mmol) and dimethyl but-2-ynedioate (**2a**; 0.250 ml, 2 mmol) at 80° for 120 min. CC (AcOEt/petroleum ether 4 : 1) and crystallization (toluene) gave 0.262 g (84%) of **5a**. M.p. 165–167°. IR (KBr): 3213, 2953, 1771, 1720, 1711, 1674, 1632, 1562, 1453, 1441, 1291, 1229, 1106, 1097, 1046, 942, 783, 756. $^1\text{H-NMR}$ (CDCl_3): 2.99 (br. s, Me_2N); 3.07 (s, MeN); 3.66 (s, COOMe); 3.86 (s, COOMe); 6.94 (br. s, NH); 7.65 (s, CHNMe_2). $^{13}\text{C-NMR}$ (CDCl_3): 24.4; 51.3; 52.6; 89.1; 115.3; 127.7; 153.0; 154.1; 160.9; 167.0; 168.2. Anal. calc. for $\text{C}_{13}\text{H}_{17}\text{N}_3\text{O}_6$ (311.29): C 50.16, H 5.50, N 13.50; found: C 50.12, H 5.73, N 13.50.

Diethyl (2E,3E)-2-[(Dimethylamino)methylene]-3-(1-methyl-2,5-dioxoimidazolidin-4-ylidene)butanedioate (5b). Prepared from **4a** (0.169 g, 1 mmol) and diethyl but-2-ynedioate (**2b**; 0.325 ml, 2 mmol) at 80° for 120 min. CC (AcOEt/petroleum ether 3 : 2) and crystallization (toluene/hexane) gave 0.213 g (63%) of **5b**. M.p. 140–143°. IR (KBr): 3208, 2986, 1759, 1714, 1678, 1626, 1594, 1456, 1387, 1280, 1218, 1097, 1023, 724, 618. $^1\text{H-NMR}$ (CDCl_3): 1.23 (t, $J = 7.1$, MeCH_2O); 1.35 (t, $J = 7.1$, MeCH_2O); 2.98 (br. s, Me_2N); 3.07 (s, MeN); 4.14–4.23 (m, 1 H, MeCH_2O); 4.27–4.36 (m, 3 H MeCH_2O); 6.76 (br. s, NH); 7.65 (s, CHNMe_2). Anal. calc. for $\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}_6$ (339.34): C 53.09, H 6.24, N 12.38; found: C 53.29, H 6.47, N 12.19.

Dimethyl (2E,3E)-2-[(Dimethylamino)methylene]-3-(5-oxo-1-phenyl-2-thioxoimidazolidin-4-ylidene)butanedioate (5c) and Dimethyl (2E,3Z)-2-[(Dimethylamino)methylene]-3-(5-oxo-1-phenyl-2-thioxoimidazolidin-4-ylidene)butanedioate (6c). Prepared from **4b** (0.247 g, 1 mmol) and dimethyl but-2-ynedioate (**2a**; 0.250 ml, 2 mmol) at 80° for 120 min. CC (AcOEt) and crystallization (AcOEt/heptane) gave 0.345 g (89%) of **5c/6c** 54 : 46 which were not separated. M.p. 136–148°. IR (KBr): 3435, 2950, 1732, 1682, 1622, 1496, 1434, 1416, 1358, 1252, 1202, 1175, 1133, 1082, 962, 733. $^1\text{H-NMR}$ (CDCl_3): (2*E*,3*E*)-

isomer **5c**: 3.21 (s, 3 H, Me₂N); 3.49 (s, 3 H, Me₂N); 3.72 (s, COOMe); 3.76 (s, COOMe); 6.74 (s, NH); 7.11 (s, CHNMe₂); 7.29–7.50 (m, Ph); (2*E*,3*Z*)-isomer **6c**: 3.25 (s, 3 H, Me₂N); 3.57 (s, 3 H, Me₂N); 3.73 (s, COOMe); 3.77 (s, COOMe); 6.28 (s, NH); 7.19 (s, CHNMe₂); 7.29–7.50 (m, Ph). Anal. calc. for C₁₈H₁₉N₃O₃S (389.43): C 55.52, H 4.92, N 10.79; found: C 55.77, H 5.11, N 10.63.

Ethyl (2*E*,3*E*)-2-[*(Dimethylamino)methylene*]-4,4,4-trifluoro-3-(1-methyl-2,5-dioximidazolidin-4-ylidene)butanoate (**5d**) and *Ethyl* (2*E*,3*Z*)-2-[*(Dimethylamino)methylene*]-4,4,4-trifluoro-3-(1-methyl-2,5-dioximidazolidin-4-ylidene)butanoate (**6d**). Prepared from **4a** (0.169 g, 1 mmol) and ethyl 4,4,4-trifluorobut-2-ynoate (**2c**; 0.220 ml, 1.33 mmol) at 80° for 120 min. CC (AcOEt/petroleum ether 1:1): 0.326 g (97%) of **5d/6d** 65:35. The isomers were separated by MPLC (AcOEt/petroleum ether 1:1). M.p. 145–148° (**5d**), 149–152° (**6d**). IR (KBr): (2*E*,3*E*)-isomer **5d**: 3215, 2984, 1779, 1724, 1698, 1644, 1611, 1462, 1399, 1283, 1257, 1214, 1173, 1126, 1082, 991, 957, 825, 763, 711; (2*E*,3*Z*)-isomer **6d**: 3237, 2983, 1767, 1725, 1699, 1648, 1614, 1457, 1398, 1329, 1271, 1245, 1215, 1193, 1109, 1048, 1027, 991, 949, 818, 764, 617. ¹H-NMR (CDCl₃): (2*E*,3*E*)-isomer **5d**: 1.22 (t, *J* = 7.1, MeCH₂O); 2.97 (br. s, Me₂N); 3.11 (s, MeN); 3.99–4.10 (m, 1 H, MeCH₂O); 4.16–4.28 (m, 1 H, MeCH₂O); 7.63 (s, CHNMe₂); 8.45 (br. s, NH); (2*E*,3*Z*)-isomer **6d**: 1.21 (t, *J* = 7.1, MeCH₂O); 2.92 (s, Me₂N); 3.08 (s, MeN); 4.01–4.24 (m, MeCH₂O); 7.69 (s, CHNMe₂); 8.47 (br. s, NH). ¹³C-NMR (CDCl₃): (2*E*,3*E*)-isomer **5d**: 14.0; 24.4; 42.6 (br. s); 60.1; 86.4 (*q*, *J* = 2.2); 112.0 (*q*, *J* = 37.2); 122.0 (*q*, *J* = 273); 131.4 (*q*, *J* = 2.2); 152.2; 153.9; 159.3; 168.0; (2*E*,3*Z*)-isomer **6d**: 14.2; 24.5; 42.8 (br. s); 59.9; 85.0 (deg. *q*); 109.7 (*q*, *J* = 32.7); 123.0 (*q*, *J* = 275); 129.3 (deg. *q*); 152.7; 153.8; 161.0; 168.5. EI-MS: 335 (*M*⁺). EI-HR-MS: 335.110030 (*M*⁺, C₁₃H₁₆F₃N₃O₄⁺; calc. 335.109291). Anal. calc. for C₁₃H₁₆F₃N₃O₄ (335.28): C 46.57, H 4.81, N 12.53; found: C 46.48, H 4.98, N 12.27.

Ethyl (2*E*,3*E*)-2-[*(Dimethylamino)methylene*]-4,4,4-trifluoro-3-(5-oxo-1-phenyl-2-thioximidazolidin-4-ylidene)butanoate (**5e**) and *Ethyl* (2*E*,3*Z*)-2-[*(Dimethylamino)methylene*]-4,4,4-trifluoro-3-(5-oxo-1-phenyl-2-thioximidazolidin-4-ylidene)butanoate (**6e**). Prepared from **4b** (0.247 g, 1 mmol) and ethyl 4,4,4-trifluorobut-2-ynoate (**2c**; 0.246 ml, 1.48 mmol) at 80° for 60 min. CC (AcOEt): 0.394 g (95%) of **5b/6e** 54:46 which were not separated. Oil. IR (KBr): 3443, 2984, 2934, 1731, 1681, 1620, 1497, 1418, 1358, 1264, 1178, 1141, 1084, 1027, 962, 733. ¹H-NMR (CDCl₃): (2*E*,3*E*)-isomer **5e**: 1.27 (t, *J* = 7.1, MeCH₂O); 3.23 (s, 3 H, Me₂N); 3.53 (s, 3 H, Me₂N); 4.20 (*q*, *J* = 7.1, MeCH₂O); 6.49 (s, NH); 7.17 (s, CHNMe₂); 7.28–7.49 (m, Ph); (2*E*,3*Z*)-isomer **6e**: 1.29 (t, *J* = 7.1, MeCH₂O); 3.26 (s, 3 H, Me₂N); 3.59 (s, 3 H, Me₂N); 4.23 (*q*, *J* = 7.1, CH₂O); 6.72 (s, NH); 7.23 (s, CHNMe₂); 7.28–7.49 (m, Ph). EI-MS: 413 (*M*⁺). EI-HR-MS: 413.103250 (*M*⁺, C₁₈H₁₈F₃N₃O₃S⁺; calc. 413.102098). Anal. calc. for C₁₈H₁₈F₃N₃O₃S (413.41): C 52.08, H 4.55, N 9.94; found: C 52.29, H 4.39, N 10.16.

Ethyl (2*E*,3*Z*)-4-(*(Dimethylamino)*)-2-(5-oxo-1-phenyl-2-thioximidazolidin-4-ylidene)but-3-enoate (**5f**) and *Ethyl* (2*E*,3*E*)-4-(*(Dimethylamino)*)-2-(5-oxo-1-phenyl-2-thioximidazolidin-4-ylidene)but-3-enoate (**7f**). Prepared from **4b** (0.247 g, 1 mmol) and ethyl prop-2-ynoate (**2d**; 0.410 ml, 4 mmol) at 100° for 210 min. CC (AcOEt) and crystallization (AcOEt/petroleum ether) gave 0.326 g (94%) of **5f/7f** 61:39 which were not separated. M.p. 136–148°. IR (KBr): 3447, 3039, 2975, 2927, 1695, 1685, 1629, 1583, 1498, 1413, 1360, 1313, 1223, 1170, 1127, 1071, 1026, 963, 735. ¹H-NMR (CDCl₃): (2*E*,3*Z*)-isomer **5f**: 1.27 (t, *J* = 7.1, MeCH₂O); 3.24 (s, 3 H, Me₂N); 3.63 (s, 3 H, Me₂N); 4.19 (*q*, *J* = 7.1, MeCH₂O); 6.10 (*d*, *J* = 10.1, H–C(3)); 7.12 (s, NH); 7.28–7.50 (m, Ph); 8.29 (*d*, *J* = 10.1, H–C(4)); (2*E*,3*E*)-isomer **7f**: 1.28 (t, *J* = 7.1, MeCH₂O); 3.23 (br. s, 3 H, Me₂N); 3.62 (br. s, 3 H, Me₂N); 4.20 (*q*, *J* = 7.1, MeCH₂O); 6.08 (*d*, *J* = 15.9, H–C(3)); 7.14 (s, NH); 7.28–7.50 (m, Ph); 8.34 (*d*, *J* = 15.9, H–C(4)). ¹³C-NMR (CDCl₃): 14.0; 39.5; 46.2; 46.3; 60.3; 60.4; 114.5; 114.9; 115.2; 118.6; 127.0; 127.2; 128.3; 128.4; 129.1; 129.2; 133.0; 133.1; 139.2; 139.5; 140.2; 140.7; 140.8; 143.8; 164.5; 166.3; 168.3; 168.7. Anal. calc. for C₁₇H₁₉N₃O₃S (345.42): C 59.11, H 5.54, N 12.17; found: C 59.27, H 5.64, N 11.99.

Dimethyl (2*E*)-2-(2,5-Dioximidazolidin-4-ylidene)butanedioate (**11**). Dimethyl but-2-ynedioate (**2a**; 0.250 ml, 2 mmol) was added to a soln. of **4c** (0.156 g, 1 mmol) in DMF (4 ml), and the mixture was stirred in a closed vessel under microwave irradiation at 80° for 180 min. The mixture was cooled, volatile components were evaporated, and the residue was purified by CC (silica gel, AcOEt/petroleum ether 1:1). The product was crystallized from AcOEt/petroleum ether: 0.112 g (46%) of **11**. M.p. 160–163°. IR (KBr): 3184, 3075, 1773, 1744, 1725, 1670, 1439, 1402, 1384, 1367, 1339, 1208, 1170, 1118, 1035, 868, 781, 757. EI-MS: 242 (*M*⁺). ¹H-NMR (D₆)(DMSO): 3.45 (s, CH₂); 3.62 (s, COOMe); 3.66 (s, COOMe); 10.54 (br. s, NH); 11.32 (br. s, NH). ¹³C-NMR ((D₆)DMSO): 34.4; 51.9; 52.0; 108.0; 132.9; 154.2; 162.2; 166.9;

168.8. EI-MS: 242 (M^+). EI-HR-MS 242.052544 (M^+ , $C_9H_{10}N_2O_6^+$; calc. 242.053886). Anal. calc. for $C_9H_{10}N_2O_6$ (242.19): C 44.63, H 4.16, N 11.57; found: C 44.83, H 4.27, N 11.53.

*X-Ray Crystal Structures of 5d, 6d, and 11*¹⁾. Single crystal X-ray diffraction data of compounds **5d**, **6d**, and **11** were collected at r.t. with a *Nonius-Kappa-CCD* diffractometer and the *Nonius Collect Software* [13]. *DENZO* and *SCALEPACK* [14] were used for indexing and scaling of the data, and the structures were solved by means of *SIR97* [15]. Refinement was done with the *Xtal3.4* [16] program package. Crystal structures were refined on F values by the full-matrix least-squares procedure. The non-H atoms were refined anisotropically in all cases, while the positions of H-atoms were geometrically calculated, and their positional and isotropic atomic displacement parameters were not refined. Absorption correction was not necessary. Regina [17] weighting scheme was used in all cases. Difference *Fourier* maps for compounds **5d**, **6d**, and **11** do not show any significant features. The crystal data and details concerning data collection and refinement for **5d**, **6d**, and **11** are given in *Table 2*. The ORTEP III [18] drawing of the content of the asymmetric unit of **5d**, **6d**, and **11** showing the atom-labeling scheme are presented in *Figs. 2, 3, and 5*.

Table 2. Crystal Data, Data Collection, and Structure Refinement for Compounds **5d**, **6d**, and **11**

	5d	6d	11
Formula	$(C_{13}H_{16}F_3N_3O_4)_2 \cdot CHCl_3$	$C_{13}H_{16}F_3N_3O_4$	$C_9H_{10}N_2O_6$
M_r	721.8	335.3	242.2
Crystal system	triclinic	monoclinic	monoclinic
Space group	$P\bar{1}$	$P2_1/a$	$P2_1/a$
a [Å]	10.2964(2)	8.6660(3)	9.63630(10)
b [Å]	12.3965(3)	12.8666(6)	12.2444(2)
c [Å]	15.7860(3)	14.0048(5)	10.2366(2)
α [Å]	88.4712(13)	90.00000	90.00000
β [°]	71.6915(12)	99.467(2)	116.0526(9)
γ [°]	78.3911(14)	90.00000	90.00000
V [Å ³]	1872.34(7)	1540.29(11)	1085.10(3)
Z	2	4	4
ρ [Mg m ⁻³]	1.401	1.446	1.482
μ [mm ⁻¹]	0.326	0.131	0.127
Color of crystal	yellow	yellow	colorless
Shape of crystal	block	block	block
Dimensions [mm]	0.14 × 0.10 × 0.08	0.22 × 0.18 × 0.14	0.20 × 0.20 × 0.12
Temperature [K]	293(1)	293(1)	293(1)
Wavelength [Å]	0.71073	0.71073	0.71073
θ_{max} [°]	27.49	27.46	27.44
No. of integrated refl.	32306	20278	15073
No. of independent refl.	8462	3500	2467
R_{int}	0.032	0.035	0.032
No. of observed reflections	5491	2372	2076
Threshold criterion	$I > 2.0\sigma(I)$	$I > 2.0\sigma(I)$	$I > 2.0\sigma(I)$
No. of refined parameters	479	208	154
Final R and R_w	0.078, 0.082	0.052, 0.053	0.044, 0.007
$(\Delta/\sigma)_{max}$	0.55	0.0002	0.0004
$\Delta\rho_{max}, \Delta\rho_{min}$ [e Å ⁻³]	–0.55, 0.60	–0.31, 0.33	–0.26, 0.30

¹⁾ CCDC-691932, -691933, and -695011 contain the supplementary crystallographic data for the structures **5d**, **6d**, and **11**, resp., described in this work. These data can be obtained, free of charge, via www.ccdc.cam.ac.uk/data_request/cif.

REFERENCES

- [1] a) C. F. Huebner, L. Dorfman, M. M. Robison, E. Doneghue, W. G. Pierson, P. Strachan, *J. Org. Chem.* **1963**, 28, 3134; b) K. C. Brannock, R. D. Burpitt, V. W. Goodlett, J. G. Thweatt, *J. Org. Chem.* **1963**, 28, 1464; c) K. C. Brannock, R. D. Burpitt, V. W. Goodlett, J. G. Thweatt, *J. Org. Chem.* **1964**, 29, 818; d) D. N. Reinhoudt, W. Verboom, G. W. Visser, W. P. Trompenaars, S. Harkema, G. J. van Hummel, *J. Am. Chem. Soc.* **1984**, 106, 1341.
- [2] B. de Ancos, M. C. Maestro, M. R. Martín, A. I. Mateo, *Tetrahedron* **1994**, 50, 13857; P. Puebla, Z. Honores, M. Medarda, L. Morán, E. Caballero, A. San Feliciano, *Tetrahedron* **1999**, 55, 7915; M.-X. Wang, W.-S. Miao, Y. Cheng, Z.-T. Huang, *Tetrahedron* **1999**, 55, 14611.
- [3] a) B. Stanovnik, *J. Heterocycl. Chem.* **1999**, 36, 1581; b) B. Stanovnik, J. Svete, *Synlett* **2000**, 1077; c) B. Stanovnik, J. Svete, 'Targets in Heterocyclic Systems, Synthesis, Reactions and Properties', Eds. O. A. Attanasi and D. Spinelli, Italian Society of Chemistry, Rome, 2000, Vol. 4, pp. 105–137; d) B. Stanovnik, J. Svete, *Chem. Rev.* **2004**, 104, 2433; e) J. Svete, *J. Heterocycl. Chem.* **2005**, 42, 361.
- [4] a) L. Selič, R. Jakše, K. Lampič, L. Golič, S. Golič Grdadolnik, B. Stanovnik, *Helv. Chim. Acta* **2000**, 83, 2802; b) L. Selič, B. Stanovnik, *Tetrahedron* **2001**, 57, 3159.
- [5] R. Jakše, J. Svete, B. Stanovnik, A. Golobič, *Tetrahedron* **2004**, 60, 4601; Z. Časar, D. Bevk, J. Svete, B. Stanovnik, *Tetrahedron* **2005**, 61, 7508.
- [6] J. Waggener, D. Bevk, A. Meden, J. Svete, B. Stanovnik, *Helv. Chim. Acta* **2006**, 89, 240; J. Waggener, S. Golič Grdadolnik, U. Grošelj, A. Meden, B. Stanovnik, J. Svete, *Tetrahedron: Asymmetry* **2007**, 18, 464; J. Waggener, U. Grošelj, A. Meden, J. Svete, B. Stanovnik, *Tetrahedron* **2008**, 64, 2801.
- [7] J. Waggener, J. Svete, B. Stanovnik, *Synthesis* **2008**, 1436.
- [8] O. A. Attanasi, G. Favi, P. Filippone, A. Golobič, B. Stanovnik, J. Svete, *J. Org. Chem.* **2005**, 70, 4307.
- [9] O. A. Attanasi, G. Favi, P. Filippone, A. Golobič, F. R. Perulli, B. Stanovnik, J. Svete, *Synlett* **2007**, 2971.
- [10] U. Uršič, U. Grošelj, A. Meden, J. Svete, B. Stanovnik, *Tetrahedron Lett.* **2008**, 49, 3775.
- [11] J. J. Titman, J. Foote, J. Jarvis, J. Keeler, D. Neuhaus, *J. Chem. Soc., Chem. Commun.* **1991**, 419; T. Ando, N. Koseki, R. F. Toia, J. E. Casida, *Magn. Reson. Chem.* **1994**, 32, 567; S. Golič Grdadolnik, B. Stanovnik, *Magn. Reson. Chem.* **1997**, 35, 482.
- [12] R. Jakše, S. Rečnik, J. Svete, A. Golobič, L. Golič, B. Stanovnik, *Tetrahedron* **2001**, 57, 8395.
- [13] Collect Software, Nonius, BV, Delft, 1998.
- [14] Z. Otwinowski, W. Minor, *Methods Enzymol.* **1997**, 276, 307.
- [15] A. Altomare, M. C. Burla, M. Camalli, G. L. Cascarano, C. Giacovazzo, A. Guagliardi, A. G. G. Moliterni, G. Polidori, R. Spagna, *J. Appl. Crystallogr.* **1999**, 32, 115.
- [16] S. R. Hall, G. S. D. King, J. M. Stewart, 'The Xtal3.4 User's Manual', University of Western Australia, Lamb, Perth, 1995.
- [17] H. Wang, B. E. Robertson, 'Structure and Statistics in Crystallography', Ed. A. J. C. Wilson, Adenine Press, New York, 1985.
- [18] M. N. Burnett, C. K. Johnson, in 'ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal Structure Illustrations', Oak Ridge National Laboratory Report ORNL-6895, 1996.

Received July 29, 2008